News and Announcements
Dysrupt Labs Semi-Annual Update 2017: $3m Raised, Product Market Fit Established, New Governance & Sports Verticals
- Published May 23, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
December 2016 Wholesale Investor round closed with $800k, and $3mn total raised for 2016.
New scalable enterprise grade Scala technology stack completed and tested in-customer.
Product-market fit validated in-customer with focused verticals in governance, management, sport & innovation.
Customer Deployments:
- Innovative new emerging risks radar and continuous audit risk and compliance
- Fan engagement with in-game forecasting of sports teams
- Continuous innovation with emerging opportunities radar
- Business metrics forecasting
At revenue with growing global customer base; half on half revenue growth of 79.5%; on budget in 1H 2017 with 2H 2017 budget revenue maintained.
Financial markets trial continues with hedge fund partner.
June 2017 Wholesale Investor funding round underway.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
